Table 4.
Characteristics of incident gallstones during lanreotide treatment versus gallstones that were present at baseline and persisted during the trial
| Incident gallstones during lanreotide treatment [n = 19] | Gallstones at baseline [n = 14] | p value | |
|---|---|---|---|
| Number of gallstones | 0.004 | ||
| 1–5 | 4 (21) | 9 (64) | |
| 5–10 | 0 (0) | 1 (7) | |
| 10–15 | 1 (5) | 3 (21) | |
| 15–20 | 1 (5) | 0 (0) | |
| 20–25 | 4 (21) | 1 (7) | |
| 25–30 | 2 (11) | 0 (0) | |
| 30+ | 7 (37) | 0 (0) | |
| Gallstone size, mm | 0.001 | ||
| ≤ 3 | 12 (63) | 2 (14) | |
| 3–10 | 7 (37) | 6 (43) | |
| ≥ 10 | 0 (0) | 6 (43) | |
| Follow-up data available until January 2020 | 16 (84) | 13 (93) | |
| Complications | 9 (56) | 0 | 0.002 |
| Pancreatitisa | 4 (25) | 0 | |
| Cholecystitis | 2 (13) | 0 | |
| Biliary colic | 2 (13) | 0 | |
| Porcelain gallbladder | 1 (6) | 0 |
Data are expressed as n (%)
Significant p-values are highlighted in bold
aOne patient developed pancreatitis during lanreotide treatment; all other complications occurred after the cessation of therapy